Transforming Coherus Adds To IO Pipeline Via Merger With Surface Oncology

16 Jun 2023

Currently battling AbbVie over pricing plans for its Humira biosimilar, Coherus is also looking to become an immuno-oncology player, acquiring two more clinical assets in an all-stock deal.

Best known as a biosimilars company, Coherus BioSciences, Inc. is trying to bolster its prospects in innovative immuno-oncology therapy by merging with the troubled Surface Oncology, Inc. through an all-stock transaction announced on 16 June. Valued at $65m and effectively doubling the size of Coherus’s IO pipeline, the deal has received unanimous approval from each company’s board of directors, which expect it to close during Q3.

The planned merger is Coherus’s second appearance in the headlines this week, as the Redwood City, CA-based firm may be...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

06 Jun 2025

• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions

05 Jun 2025

• By Andrew McConaghie

As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.

Deal Watch: Lilly Licenses Camurus’s Delivery Technology For Long-Acting Incretins

04 Jun 2025

• By Joseph Haas

Plus deals involving Roche/Vividion, Alto/Chase, Biogen/City Therapeutics, Sanofi/Nurix and Naya/Invo.

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

04 Jun 2025

• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.